Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

About this update from Telomir Pharmaceuticals, Inc.

[{"type":"text","content":"Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026","length":155,"tagName":"p"},{"type":"text","content":"MIAMI, FL / ACCESS Newswire / June 2, 2025 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced its participation in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has scheduled a full week of BIO One-on-One Partnering™ meetings to explore strategic collaborations, licensing opportunities, and potential M&A transactions.","length":483,"tagName":"p"},{"type":"text","content":"Telomir is actively preparing to submit an Investigational New Drug (IND) application by the end of this year for its lead candidate, Telomir-1-a novel small molecule designed to elongate telomeres, regenerate cells, and reverse core mechanisms of biological aging. The Company is gearing up for its pre-IND meeting with the FDA, with the goal of initiating first-in-human dosing in the first half of 2026.","length":406,"tagName":"p"},{"type":"text","content":"As part of its expanding pipeline, Telomir is advancing a rare-disease exploratory and developmental strategy focused on high-need orphan indications where cellular aging plays a central role. These include:","length":207,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Werner's syndrome, a rare adolescent- or adult-onset disorder often referred to as "adult Progeria," which is expressed by many features of premature aging, including early graying, cataracts, metabolic dysfunction, and cancer predisposition.","length":256,"tagName":"p"}]},{"val":[{"type":"text","content":"Wilson's disease, a rare genetic disorder caused by copper accumulation in tissues. Telomir-1 has already demonstrated in preclinical testing copper-modulating capabilities, reversal of copper-induced toxicities and reactive oxygen species production, offering a potential disease-modifying approach that directly addresses the root cause of toxicity and inflammation associated with Wilson's.","length":401,"tagName":"p"}]},{"val":[{"type":"text","content":"Progeria, an ultra-rare pediatric condition that causes rapid aging in chi...

More updates from Telomir Pharmaceuticals, Inc.